Licensing PARP Inhibitor A Win For BioMarin, Medivation
BioMarin’s licensing of the PARP inhibitor talazoparib to Medivation in August reduces BioMarin’s development expenses and helps it to meet its stated goal of being non-GAAP earnings positive in 2017. Medivation gets another compound it can develop in key oncology indications it is already pursuing with its core product, the prostate cancer drug Xtandi.
You may also be interested in...
Big pharma keeps marching into immuno-oncology, and partnering in the field has been one of the biggest deal drivers of 2015. It’s not yet a big factor in M&A, which this year has been driven by payer pressure and generics consolidation.
Kuvan-launch mistakes and the Riquent fizzle take their toll, as company shops for workable assets.
For biopharma, launching first products, and especially sudden profitability, doesn't necessarily predict which companies will succeed. Instead, an examination of stock market success shows the need to bring a succession of drugs, or at least additional indications, into clinical trials-mostly through aggressive deal-making.